The AI Biologist for smarter drug development
Meta-Flux is a Dublin-based biotech startup building an 'AI Biologist' for pharmaceutical drug development. The platform uses feedback-loop knowledge graphs and multi-scale simulation models to process 20+ trillion biological data points across genes, proteins, metabolites, and patient phenotypes. It enables pharma teams to run rapid hypothesis-to-insight cycles, identify drug repurposing opportunities, flag off-target toxicity risks, and validate targets before costly preclinical work begins. Meta-Flux has demonstrated 97% diagnostic accuracy in sepsis disease modelling and ROC AUC of 0.994 in lung cancer biomarker identification. Founded in 2021 by Lee Sherlock (immunologist, Trinity College) and Brendan Martin (CTO), the company raised a $2.1M seed round in 2025 backed by executives from Pfizer, Merck, and Gilead Sciences.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNo funding data available yet.
Know something? Help us improve our data.
Create a free account to see which investors have funded this company.
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
